Expert Network Best Practices, Part II: Interpreting the SEC’s Risk Alert on MNPI
14 July 2022
Foley Partner Jim Lundy will join an ACA Group panel of subject-matter experts to examine the U.S. Securities and Exchange Commission’s (SEC) Division of Examinations recent risk alert highlighting common deficiencies in material non-public information (MNPI) observed during examinations. The panelists will discuss why these deficiencies are so common and how your firm can avoid making the same mistakes.
Key learning objectives:
- Rules about the use of Expert Networks and other research
- Use of alternative data outlined in the risk alert
- Application of the SEC’s “shadow trading” theory
- How your advisors and vendors can help you comply
In addition to Jim Lundy, the speakers include:
- Carlo di Florio, Chief Services Officer, ACA Group
- Dan Campbell, Director, ACA Group
- Jason Howard, GC/CCO, Tegus
There is no charge to attend this webinar. To register, click here.
People
Related Insights
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…
July 23, 2025
Health Care Law Today
Update: CMS Extends Skilled Nursing Facilities’ Medicare Revalidation Deadline
On April 17, 2025, the Centers for Medicare and Medicaid Services (CMS) announced another extension of the deadline by which skilled nursing facilities (SNFs) must revalidate their Medicare enrollments.
July 22, 2025
Health Care Law Today
GLP-1 Receptor Agonists: Clinical Trial Considerations
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®).